Related by context. Frequent words. (Click for all words.) 59 through ImmunoGen collaborations 58 AVI RNA based 58 modulate ion channel 58 diagnostic biomarkers 58 HMG CoA reductase inhibitors 57 GSK# [002] 57 myeloproliferative disorders 57 novel antibody therapeutics 57 CEQ# 56 multi kinase inhibitor 56 Belimumab 56 VEGFR2 inhibitor 56 huC# DM4 56 Carfilzomib 56 2 methoxyestradiol 56 Sapacitabine 56 Entereg R 56 generation proteasome inhibitor 55 immuno inflammatory diseases 55 peripherally acting 55 Vytorin combines 55 Romidepsin 55 JAK inhibitor 55 R sorafenib tablets 54 identify protein biomarkers 54 gastrointestinal mucositis 54 Panzem R NCD 54 Phase Ib clinical trials 54 AEG# 53 coagulation disorders 53 ALN TTR 53 Nanobody 53 systemically administered 53 Indibulin 53 splice variants 53 Prodarsan ® 53 molecular biomarkers 53 metastatic colorectal 53 inflammatory autoimmune diseases 52 oral antiviral 52 Xanafide 52 ganetespib 52 REGN# 52 MEK inhibitors 52 predictive biomarkers 52 HGS ETR2 52 G Protein Coupled 52 RGB # 52 dose pharmacokinetic 52 AVE# 52 phase IIb clinical 52 PRT# 52 Copegus R 52 elotuzumab 51 nucleoside reverse transcriptase inhibitor 51 primary hypercholesterolemia 51 Alagebrium 51 therapeutic monoclonal antibodies 51 pomalidomide 51 multiple sclerosis rheumatoid arthritis 51 placebo controlled clinical trials 51 rheumatoid arthritis multiple sclerosis 51 rheumatoid arthritis psoriatic arthritis 51 preclinical efficacy 51 siRNA therapeutic 51 Venjah K. Hunte 51 wife Yessica Guerrero 51 SCH # 51 BMS # 51 Initiates Phase II 51 TLR8 51 hemorrhagic fever viruses 51 EGFR pathway 51 intracellular signaling pathways 50 Meets Primary Endpoint 50 TACI Ig 50 TLR9 agonists 50 prognostic markers 50 Inc. Nasdaq IMGN 50 immunological diseases 50 dose limiting toxicities 50 ® bortezomib 50 Azedra 50 immunologic diseases 50 PEG SN# 50 docetaxel chemotherapy 50 painkillers oxycodone 50 dose regimens 50 mTOR inhibitors 50 HGS ETR1 50 diabetic neuropathic pain 50 deforolimus 50 nonclinical studies 50 phase IIa clinical 50 liposomal formulation 50 essential thrombocythemia 50 events SAEs 50 Phase 2b clinical trials 50 Phase Ib II 49 Sym# 49 varespladib